Treatment with anti-vegf antibodies

Abstract

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

1 . A method of treating metastatic renal cancer in a human patient, comprising administering to the patient effective amounts of an anti-VEGF antibody and an anti-neoplastic composition, wherein said anti-neoplastic composition comprises at least one chemotherapeutic agent and wherein said anti-VEGF antibody is bevacizumab. 
   
   
       2 . The method of  claim 1 , wherein the anti-VEGF antibody is administered concomitantly with the at least one chemotherapeutic agent. 
   
   
       3 . The method of  claim 1 , wherein the patient is previously untreated. 
   
   
       4 . The method of  claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folic acid analogs, pyrimidine analogs, purine analogs and related inhibitors, vinca alkaloids, epipodopyyllotoxins, antibiotics, L-Asparaginase, topoisomerase inhibitor, interferons, platinum coordination complexes, anthracenedione substituted urea, methyl hydrazine derivatives, adrenocortical suppressant, adrenocorticosteroides, progestins, estrogens, antiestrogen, androgens, antiandrogen, and gonadotropin-releasing hormone analog. 
   
   
       5 . The method of  claim 4 , wherein said at least one chemotherapeutic agent is an interferon. 
   
   
       6 . The method of  claim 5 , wherein the anti-VEGF antibody is administered intravenously. 
   
   
       7 . The method of  claim 6 , wherein the anti-VEGF antibody is administered to the patient at about 5 mg/kg to about 15 mg/kg. 
   
   
       8 . The method of  claim 7 , wherein the anti-VEGF antibody is administered by intravenous infusion over 30-90 minutes.